|
US20030044384A1
(en)
*
|
1997-10-09 |
2003-03-06 |
Pro-Virus, Inc. |
Treatment of neoplasms with viruses
|
|
EP1955703A1
(en)
|
1999-11-12 |
2008-08-13 |
Oncolytics Biotech Inc. |
Viruses for the treatment of cellular proliferative disorders
|
|
AUPQ425699A0
(en)
|
1999-11-25 |
1999-12-23 |
University Of Newcastle Research Associates Limited, The |
A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
|
|
CA2382998A1
(en)
*
|
1999-12-08 |
2001-06-14 |
Onyx Pharmaceuticals, Inc. |
Mutant simplex virus for treating unwanted hyperproliferative cell growth
|
|
US8491884B2
(en)
|
2000-05-03 |
2013-07-23 |
Oncolytics Biotech Inc. |
Virus clearance of neoplastic cells from mixed cellular compositions
|
|
AR028039A1
(es)
|
2000-05-03 |
2003-04-23 |
Oncolytics Biotech Inc |
Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
|
|
US7306902B2
(en)
|
2002-06-28 |
2007-12-11 |
Oncolyties Biotech Inc. |
Oncolytic viruses as phenotyping agents for neoplasms
|
|
AR028040A1
(es)
*
|
2000-05-03 |
2003-04-23 |
Oncolytics Biotech Inc |
Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas
|
|
US20020147996A1
(en)
*
|
2000-07-07 |
2002-10-10 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using Sal2
|
|
US20030157481A1
(en)
*
|
2001-12-10 |
2003-08-21 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using T-HR mutants and their targets
|
|
US20050013803A1
(en)
*
|
2000-07-07 |
2005-01-20 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using mutant viruses
|
|
US20020156039A1
(en)
*
|
2000-07-07 |
2002-10-24 |
Benjamin Thomas L. |
Diagnosing and treating cancer cells using Sal2
|
|
US6982251B2
(en)
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
JP4711600B2
(ja)
|
2001-01-26 |
2011-06-29 |
シェーリング コーポレイション |
シトステロール血症の処置のための置換アゼチジノン化合物の使用
|
|
US7071181B2
(en)
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
|
SI1413331T1
(sl)
|
2001-01-26 |
2008-02-29 |
Schering Corp |
Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
|
|
AR035227A1
(es)
|
2001-02-20 |
2004-05-05 |
Oncolytics Biotech Inc |
Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
|
|
US7132415B2
(en)
|
2001-09-21 |
2006-11-07 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
|
|
US7053080B2
(en)
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
|
US7056906B2
(en)
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
|
EP1499355A4
(en)
*
|
2001-12-07 |
2005-10-05 |
Bayer Pharmaceuticals Corp |
USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES
|
|
IL163745A0
(en)
*
|
2002-03-26 |
2005-12-18 |
Oncolytics Biotech Inc |
Use of adenoviruses mutated in the va genes for cancer treatment
|
|
EP1515747A4
(en)
*
|
2002-04-26 |
2006-05-10 |
Wellstat Biologics Corp |
THERAPY WITH AN IMMUNOGENIC AGENT USING PLASMAPHERESIS OR EXCHANGE TRANSFUSION
|
|
US20040180438A1
(en)
*
|
2002-04-26 |
2004-09-16 |
Pachuk Catherine J. |
Methods and compositions for silencing genes without inducing toxicity
|
|
WO2004009763A2
(en)
|
2002-07-24 |
2004-01-29 |
Arizona Board Of Regents |
Use of vaccinia virus deleted for the e3l gene as a vaccine vector
|
|
EP2269618A1
(en)
|
2002-08-12 |
2011-01-05 |
Jennerex Biotherapeutics ULC |
An oncolytic vaccinia virus for use in combination with a chemotherapy for treating cancer.
|
|
CA2504878A1
(en)
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorption inhibitors for the treatment of demyelination
|
|
AU2002953436A0
(en)
|
2002-12-18 |
2003-01-09 |
The University Of Newcastle Research Associates Limited |
A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
|
|
CN1756755A
(zh)
|
2003-03-07 |
2006-04-05 |
先灵公司 |
取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
|
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
JP4589919B2
(ja)
|
2003-03-07 |
2010-12-01 |
シェーリング コーポレイション |
高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
|
|
CN100439361C
(zh)
|
2003-03-07 |
2008-12-03 |
先灵公司 |
取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
|
|
RU2376371C2
(ru)
|
2003-06-18 |
2009-12-20 |
Дженелюкс Корпорейшн |
Модифицированные рекомбинантные вакцинирующие вирусы и другие микроорганизмы и их применение
|
|
EP1648233A4
(en)
*
|
2003-07-08 |
2006-08-23 |
Univ Arizona |
MUTANTS OF VACCINIA VIRUS AS ONCOLYTICA
|
|
US7442372B2
(en)
|
2003-08-29 |
2008-10-28 |
Biomarin Pharmaceutical Inc. |
Delivery of therapeutic compounds to the brain and other tissues
|
|
WO2006031996A2
(en)
*
|
2004-09-14 |
2006-03-23 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Targeting viruses using a modified sindbis glycoprotein
|
|
US20060160837A1
(en)
*
|
2004-12-29 |
2006-07-20 |
The Brigham And Women's Hospital, Inc. |
Rapamycin compounds in the treatment of neurofibromatosis type 1
|
|
DK1855720T4
(da)
*
|
2005-02-23 |
2023-07-24 |
Bavarian Nordic As |
Anvendelse af et modificeret poxvirus til hurtig induktion af immunitet mod et poxvirus eller andre smitstoffer
|
|
CN101137748B
(zh)
*
|
2005-03-07 |
2011-12-14 |
罗巴斯研究机构 |
粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用
|
|
US20070004767A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Gutmann David H |
Methods for treating neurofibromatosis 1
|
|
EP1917351A4
(en)
|
2005-08-01 |
2009-12-16 |
Univ Technologies Int |
WEAKEN REOVIRUS
|
|
US10668119B2
(en)
|
2005-08-01 |
2020-06-02 |
Virocure, Inc. |
Attenuated reovirus
|
|
US8980246B2
(en)
|
2005-09-07 |
2015-03-17 |
Sillajen Biotherapeutics, Inc. |
Oncolytic vaccinia virus cancer therapy
|
|
EP1933857A2
(en)
|
2005-09-07 |
2008-06-25 |
Jennerex Biotherapeutics ULC |
Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses
|
|
AU2007215328A1
(en)
*
|
2006-02-13 |
2007-08-23 |
Oncolytics Biotech Inc. |
Use of local immune suppression to enhance oncolytic viral therapy
|
|
WO2008100292A2
(en)
|
2006-10-16 |
2008-08-21 |
Genelux Corporation |
Modified vaccinia virus strains for use in diagnostic and therapeutic methods
|
|
US10369171B2
(en)
|
2007-03-13 |
2019-08-06 |
Virocure, Inc. |
Attenuated reoviruses for selection of cell populations
|
|
WO2008156655A2
(en)
|
2007-06-15 |
2008-12-24 |
Genelux Corporation |
Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
|
|
EP2173368A1
(en)
*
|
2007-07-18 |
2010-04-14 |
Genelux Corporation |
Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy
|
|
WO2009135614A2
(en)
*
|
2008-05-09 |
2009-11-12 |
Bayer Schering Pharma Aktiengesellschaft |
Use of a virus regimen for the treatment of diseases
|
|
US20120052003A9
(en)
*
|
2008-05-16 |
2012-03-01 |
Szalay Aladar A |
Microorganisms for preventing and treating neoplasms accompanying cellular therapy
|
|
US20110086005A1
(en)
*
|
2008-05-27 |
2011-04-14 |
Oncolytics Biotech Inc. |
Modulating interstitial pressure and oncolytic viral delivery and distribution
|
|
ES2645692T3
(es)
|
2008-11-11 |
2017-12-07 |
The Board Of Regents,The University Of Texas System |
Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
|
|
WO2011032180A1
(en)
|
2009-09-14 |
2011-03-17 |
Jennerex, Inc. |
Oncolytic vaccinia virus combination cancer therapy
|
|
US9283211B1
(en)
|
2009-11-11 |
2016-03-15 |
Rapamycin Holdings, Llc |
Oral rapamycin preparation and use for stomatitis
|
|
EP2661278B1
(en)
|
2011-01-04 |
2019-06-19 |
SillaJen Biotherapeutics, Inc. |
Tumor specific complement dependent cytotoxicity (cdc) antibodies generated by administration of oncolytic vaccinia virus, for use in the treatment of cancer
|
|
WO2012122649A1
(en)
*
|
2011-03-15 |
2012-09-20 |
Ottawa Hospital Research Institute |
Recombinant orf virus
|
|
CA2836299A1
(en)
|
2011-04-15 |
2012-10-18 |
Genelux Corporation |
Clonal strains of attenuated vaccinia viruses and methods of use thereof
|
|
US8859256B2
(en)
|
2011-10-05 |
2014-10-14 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
EP2968281B1
(en)
|
2013-03-13 |
2020-08-05 |
The Board of Regents of The University of Texas System |
Mtor inhibitors for prevention of intestinal polyp growth
|
|
KR102089121B1
(ko)
|
2013-03-14 |
2020-03-13 |
더 솔크 인스티튜트 포 바이올로지칼 스터디즈 |
종양살상형 아데노바이러스 조성물
|
|
DE102013105144A1
(de)
*
|
2013-05-17 |
2014-11-20 |
Arno Thaller |
Pharmazeutisches Kombinationspräparat mit einem anti-idiotypischen Antikörperfragment
|
|
DK3089737T3
(da)
|
2013-12-31 |
2021-12-13 |
Rapamycin Holdings Llc |
Orale rapamycin-nanopartikelpræparater og anvendelse.
|
|
US9700544B2
(en)
|
2013-12-31 |
2017-07-11 |
Neal K Vail |
Oral rapamycin nanoparticle preparations
|
|
EP3198009B1
(en)
|
2014-09-24 |
2021-09-08 |
Salk Institute for Biological Studies |
Oncolytic tumor viruses and methods of use
|
|
NZ732211A
(en)
|
2014-10-24 |
2020-04-24 |
Calidi Biotherapeutics Inc |
Combination immunotherapy approach for treatment of cancer
|
|
US10639366B2
(en)
|
2015-02-25 |
2020-05-05 |
Memorial Sloan Kettering Cancer Center |
Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
|
|
KR20180006916A
(ko)
|
2015-04-17 |
2018-01-19 |
메모리얼 슬로안-케터링 캔서 센터 |
고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
|
|
JP6788663B2
(ja)
|
2015-08-11 |
2020-11-25 |
カリディ・バイオセラピューティクス・インコーポレイテッドＣａｌｉｄｉ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
癌処置のための天然痘ワクチン
|
|
KR102762431B1
(ko)
|
2016-01-08 |
2025-02-03 |
레플리뮨 리미티드 |
변형된 항종양 바이러스
|
|
CN105754952B
(zh)
*
|
2016-02-16 |
2020-07-10 |
中国农业科学院兰州兽医研究所 |
抗羊痘病毒k3l蛋白c末端的单克隆抗体及其应用
|
|
JP7015551B2
(ja)
|
2016-02-23 |
2022-02-15 |
ソーク インスティテュート フォー バイオロジカル スタディーズ |
ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
|
|
EP3390428B1
(en)
|
2016-02-23 |
2019-09-25 |
Salk Institute for Biological Studies |
High throughput assay for measuring adenovirus replication kinetics
|
|
KR20180130500A
(ko)
|
2016-02-25 |
2018-12-07 |
메모리얼 슬로안 케터링 캔서 센터 |
인간 flt3l을 발현하는 재조합 mva 또는 mvaδe3l 및 고형 종양에 대한 면역요법제로서 그의 용도
|
|
AU2017222686B2
(en)
|
2016-02-25 |
2021-12-23 |
Memorial Sloan Kettering Cancer Center |
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
|
|
KR20190007416A
(ko)
*
|
2016-03-25 |
2019-01-22 |
유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
합성적으로 엔벨롭된 바이러스
|
|
US10842835B2
(en)
|
2016-05-25 |
2020-11-24 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Oncolytic vaccinia virus mutants and using same for cancer treatment
|
|
CN109844104B
(zh)
|
2016-07-21 |
2023-04-28 |
可隆生命科学株式会社 |
重组疫苗病毒及其用途
|
|
JP7794421B2
(ja)
|
2016-12-12 |
2026-01-06 |
ソーク インスティテュート フォー バイオロジカル スタディーズ |
腫瘍を標的にする合成アデノウイルスおよびその使用
|
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
|
EP3621646A4
(en)
|
2017-05-12 |
2021-06-02 |
Memorial Sloan Kettering Cancer Center |
VACCINIA VIRUS MUTANTS FOR CANCER IMMUNOTHERAPY
|
|
US10610583B2
(en)
|
2017-08-31 |
2020-04-07 |
Regents Of The University Of Minnesota |
Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus
|
|
KR102267837B1
(ko)
*
|
2018-01-19 |
2021-06-22 |
코오롱생명과학 주식회사 |
재조합 백시니아 바이러스 및 이를 포함하는 약학 조성물
|
|
BR112020019942A2
(pt)
|
2018-04-09 |
2021-01-26 |
Salk Institute For Biological Studies |
composições de adenovírus oncolítico com propriedades de replicação aprimoradas
|
|
US11505782B2
(en)
|
2018-06-04 |
2022-11-22 |
Calidi Biotherapeutics, Inc. |
Cell-based vehicles for potentiation of viral therapy
|
|
CN116162654A
(zh)
|
2018-09-15 |
2023-05-26 |
纪念斯隆凯特琳癌症中心 |
用于癌症免疫疗法的重组痘病毒
|
|
CN114364390A
(zh)
*
|
2019-08-26 |
2022-04-15 |
拜耳诺克斯有限公司 |
用于治疗癌症的包含抗癌病毒、免疫检查点抑制剂和羟基脲作为活性成分的药物组合物
|